Skip to main content
An official website of the United States government
The SBIR and STTR programs were reauthorized on April 13, 2026. Currently, NIH has no active SBIR or STTR Notices of Funding Opportunity (NOFOs). Future NOFOs are forecasted at Grants.gov prior to opening for applications. The next standard receipt date is September 5, 2026.
Email

NCI SBIR/STTR Omnibus Grant Solicitations

The Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) Omnibus Solicitations are intended to support small business innovation research across a broad spectrum of topic areas. 

U.S. small businesses that have the research capabilities and technological expertise to contribute to the research and development missions of the awarding components identified in the Omnibus Solicitation are encouraged to submit investigator-initiated SBIR & STTR grant applications in response to the identified topics. Applicants may also consider other areas of research within the mission of any of the awarding components and submit an SBIR & STTR application

Small business concerns that are majority-owned by multiple venture capital operating companies (VCOCs), hedge funds and/or private equity firms continue to be eligible to apply to the CDC and NIH SBIR program and compete for up to 15% and 25% respectively of each agency's SBIR set-aside.

Omnibus Solicitation Opportunities

This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.

Application Resources: 

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “NCI SBIR/STTR Omnibus Grant Solicitations was originally published by the National Cancer Institute.”

Email